Aside from share price ... smells right for some bolt-onsThis environment that we are seeing in biotech is typically a good period for Goodman's team.
A green light to buy may be close.
They are waiting for the markets to get ugly and then they might make a few bolt-on deals.
If anything comes in 2023, might be small deals and watch for a few to happen all-at-once.
GUD isn't interested in telegraphing that it's doing some buying - so - if they make some pick-ups, they just might structure them to happen at exactly the same time.
Just watching for it - but - nothing is guaranteed with these guys/gals.
-------------
Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon.
With reality setting in, it’s a buyer’s market for companies looking for acquisitions and partnerships, according to many of the pharmaceutical and medical technology executives who gathered at this year’s healthcare investor conference, which wrapped up in San Francisco on Thursday.
{Barron's - Biotech & Pharma}